Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling

Metastatic melanoma remains an incurable disease for many patients due to the limited success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic burden for patients with melanomas harboring BRAF mutations; however, most eventually relapse due to acquired resistance. Here, we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Commun
Hlavní autoři: Tripathi, Rakshamani, Liu, Zulong, Jain, Aditi, Lyon, Anastasia, Meeks, Christina, Richards, Dana, Liu, Jinpeng, He, Daheng, Wang, Chi, Nespi, Marika, Rymar, Andrey, Wang, Peng, Wilson, Melissa, Plattner, Rina
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596241/
https://ncbi.nlm.nih.gov/pubmed/33122628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-19075-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky